<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cir Dig</journal-id>
      <journal-id journal-id-type="iso-abbrev">Arq Bras Cir Dig</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cirurgia Digestiva : ABCD = Brazilian Archives of Digestive Surgery</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0102-6720</issn>
      <issn pub-type="epub">2317-6326</issn>
      <publisher>
        <publisher-name>Col&#xE9;gio Brasileiro de Cirurgia Digestiva</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25861079</article-id>
      <article-id pub-id-type="pmc">4739257</article-id>
      <article-id pub-id-type="doi">10.1590/S0102-67202015000100022</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter To The Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>GASTROINTESTINAL STROMAL TUMOR OF THE RECTUM TREATED WITH NEOADJUVANT
IMATINIB FOLLOWED BY TRANSANAL ENDOSCOPIC MICROSURGERY</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Tumor gastrointestinal estromal de reto tratado com imitanib
neoadjuvante seguido de microcirurgia endosc&#xF3;pica transanal</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>NAHAS</surname>
            <given-names>Caio Sergio Rizkallah</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>NAHAS</surname>
            <given-names>Sergio Carlos</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MARQUES</surname>
            <given-names>Carlos Frederico Sparapan</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>SCHMERLING</surname>
            <given-names>Rafael</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>BUSTAMANTE-LOPEZ</surname>
            <given-names>Leonardo Alfonso</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>RIBEIRO</surname>
            <given-names>Ulysses</given-names>
            <suffix>JUNIOR</suffix>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>CECCONELLO</surname>
            <given-names>Ivan</given-names>
          </name>
        </contrib>
        <aff>From the Department of Gastroenterology, Surgical Division, Clinic Hospital, School
of Medicine, University of S&#xE3;o Paulo, S&#xE3;o Paulo, Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01"><bold>Correspondence:</bold> Caio Sergio Rizkallah Nahas E-mail:
<email>caionahas@uol.com.br</email></corresp>
        <fn fn-type="conflict">
          <p>Conflicts of interest: none</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Mar</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Mar</season>
        <year>2015</year>
      </pub-date>
      <volume>28</volume>
      <issue>1</issue>
      <fpage>87</fpage>
      <lpage>89</lpage>
      <history>
        <date date-type="received">
          <day>05</day>
          <month>12</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>11</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The gastrointestinal stromal tumor (GIST) is a rare type of tumor that expresses CD117
oncogene that can be detected by immunohistochemistry<sup><xref rid="r02" ref-type="bibr">2</xref></sup>. The most common sites of GISTs are stomach (70%), and
small intestine (20%), while rectum is comprised in only 3% of the cases<sup><xref rid="r05" ref-type="bibr">5</xref></sup>. Although a rare condition, the GIST
located in the distal rectum may require an abdominoperineal resection. There is no data
to support the use of Imatinib (Gleevec from Novartis, Basel, Switzerland), a selective
inhibitor of tyrosine quinase, as neoadjuvant therapy. However, the last session
consensus for the treatment of GIST, suggests that this form of therapy can be used in
some cases where anal sphincter is involved<sup><xref rid="r07" ref-type="bibr">7</xref></sup>. The objective of this report is to describe a case of GIST distal
rectum in the rectovaginal septum with partial invasion of the anal sphincter, which was
successfully treated by neoadjuvant therapy with imatinib followed by the technique of
transanal endoscopic microsurgery (TEM). The results are compared with experience in the
literature.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 63-years-old female patient was sent to the hospital with complaints of mild
constipation. A clinical examination did not detect any palpable abdominal mass. Rectal
digital exam revealed a 5 cm mass in the left anterior rectal wall, located 2 cm above
the dentate line. The mass was solid, with a smooth and regular surface. Colonoscopy
confirmed the presence of a round and regular mass, covered by normal mucosa, measuring
about 5 cm in diameter, in the left anterior wall. A transrectal biopsy with Tru-cut
needle was performed. Immunohistochemical positivity for CD117 and CD34 antigens, and
negative for smooth muscle actin or S-100 protein confirmed the diagnosis of a
submucosal rectal GIST. The mitotic activity was 2&#xD7;10 high power field (HPF), and there
was absence of necrosis. Computed tomography showed the presence of a tumor of
5.2x5.0x5.6 cm, irregular, with eccentric thickening of the left anterior rectal wall in
the lower rectum, with close contact with the posterior vaginal wall and partial
invasion of the levator ani muscle, but with no evidence of lymph node or distant
metastases (<xref ref-type="fig" rid="f01">Figure 1</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>TC showing the presence of a 5.2x5.0x5.6 cm mass with a marked, irregular,
eccentric thickening of the left anterior rectal wall of the lower third of the
rectum, with close contact with the posterior vaginal wall and partial invasion of
the levator ani muscle.</p>
        </caption>
        <graphic xlink:href="abcd-28-01-0087-g01"/>
      </fig>
      <p>As curative surgery would have implied abdominoperineal resection with permanent
colostomy, treatment with Imatinib at a standard dose (400 mg/day) was started. Response
to treatment was evaluated using CT every three months. Maximal response was obtained at
six months, which was maintained after eight months of treatment. At that time, a pelvic
MRI showed a partial diminution of the mass dimensions (4.0x3.0x3.1 cm), but still
occupying the rectovaginal septum, with close contact of the cranial portion of levator
ani muscle (<xref ref-type="fig" rid="f02">Figure 2</xref>).</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Assessment of tumour response to Imatinib: MRI showing a predominantly exophytic,
heterogenous, submucosal mass (measuring 4.0x3.0x 3.1 cm) on the left anterior
rectal wall occupying the rectovaginal septum, with partial invasion of the
cranial portion of levator ani muscle.</p>
        </caption>
        <graphic xlink:href="abcd-28-01-0087-g02"/>
      </fig>
      <p>The partial tumour mass reduction was enough to allow a local excision using the
transanal endoscopic microsurgery (TEM) technique. The tumor mass was completely excised
en-bloc with part of the posterior wall of the vagina and a minimal portion of tissue
from the levator ani muscle (<xref ref-type="fig" rid="f03">Figure 3</xref>).</p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Surgical specimen with tumor mass completely excised en-bloc with part of the
posterior wall of the vagina and a minimal portion of tissue from the levator ani
muscle</p>
        </caption>
        <graphic xlink:href="abcd-28-01-0087-g03"/>
      </fig>
      <p>The rectal wall defect was closed primarily. For that, a flap of rectal wall was
advanced to the anal verge. The suture consisted of conventional hand-sewn interrupted
stitches (<xref ref-type="fig" rid="f04">Figure 4</xref>).</p>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Rectal wall defect closure with conventional hand-sewn interrupted suture</p>
        </caption>
        <graphic xlink:href="abcd-28-01-0087-g04"/>
      </fig>
      <p>TEM suturing technique could not be used in this case since it was not possible to keep
the gas insufflation at the anal verge (the TEM retoscope could not seal the anus). The
vaginal wall was also closed primarily with a transvaginal running suture. A
laparoscopic loop ileostomy was created to prevent from rectovaginal fistulae. The
postoperative period was uneventful and the patient was sent home on 4<sup>th</sup> day.
The loop ileostomy was taken down four months later and the patient recovered normal
defecation with minimal transient fecal incontinence. Pathological analysis of the
surgical specimen identified a white firm 3.5x3.0x3.0 cm well delimited rectal mass,
occupying the muscularis mucosa, submucosa, muscular propria, and the adjacent soft
tissue close to the vagina interface. The specimen margins were free of tumor. The
lesion expressed CD34 or CD117 and showed no mitotic activity (zero mitoses in 50 HPF).
As for now, the patient presented no evidence of recurrence of disease (follow up period
of 46.2 months).</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>As the incidence of GIST of the rectum is so low, there are only data from few small
series and case reports in the PubMed indexed English literature<sup><xref rid="r02" ref-type="bibr">2</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup>. It is generally agreed that complete surgical resection with negative
tumor margins is the principal curative procedure for primary and non-metastatic tumors,
particularly for those at a low risk<sup><xref rid="r02" ref-type="bibr">2</xref></sup>.
Various surgical procedures may be considered, including conventional transanal local
excision<sup><xref rid="r05" ref-type="bibr">5</xref></sup>, transperineal local
excision<sup><xref rid="r04" ref-type="bibr">4</xref></sup>, abdomino-perineal
resection<sup><xref rid="r03" ref-type="bibr">3</xref></sup>, transacral
excision<sup><xref rid="r10" ref-type="bibr">10</xref></sup>, low anterior
resection of the rectum<sup><xref rid="r06" ref-type="bibr">6</xref></sup> and
TEM<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. The choice of procedure
depends on tumor size and location. Imatinib is reserved for the treatment of patients
with advanced GIST, in the adjuvant postoperative treatment of high risk tumors or in
cases of incomplete surgical resection. Although further evidence for the efficiency of
this drug in the neoadjuvant setting is still needed, it is believed that Imatinib may
enhance the resectability of inoperable malignant GIST and may allow for optimal
surgical timing, especially when there is intent to spare the anal sphincter in patients
with low rectal tumors. The optimal duration of preoperative Imatinib for patients with
locally advanced GIST is unknown. The median time to best response in all responding
patients was about four months (107 days), and most responses happened in nine months of
treatment<sup><xref rid="r08" ref-type="bibr">8</xref></sup>.</p>
      <p>After reviewing the PubMed indexed English literature of the last 10 years, was found 53
cases of patients with rectal GIST treated with neoadjuvant Imatinib<sup><xref rid="r02" ref-type="bibr">2</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup>. The indications for neoadjuvant imatinib were: patients that were
initially considered unresectable, or patients that have initial indication for
extensive surgery (including anal sphincter resection). In only one of these cases,
radiation was added to Imatinib<sup><xref rid="r06" ref-type="bibr">6</xref></sup>. A
sphincter-saving procedure was performed in 42 patients (21 conventional transanal local
excision, 16 low anterior resection, four transacral resection, one transperineal local
excision, and one TEM). The pathological examination documented a complete pathological
response in seven cases.</p>
      <p>This case is the second in the literature in which the tumor could be removed by TEM.
This technique allowed us to perform a full thickness resection of the rectal wall
(combined with en-bloc resection of the posterior vaginal wall), with complete resection
of the tumor. The procedure was safe and obeyed the oncologic principles.</p>
      <p>Since the incidence of rectal GIST is much lower than that of GIST in the stomach or
small intestine, the clinicopathological profiles of rectal GIST have not yet been
accurately characterized, and there is therefore the tendency to validate the same
prognostic factors for the latter as for such tumors at other sites, particularly
gastric GIST. The most important and easily applicable histological criteria for
prediction of GIST are its size and mitotic rate. A rate of &#x2264; five mitoses per 50
HPF is commonly used as a limit for a tumor with expected benign behavior, and according
to a large study, this can discriminate between benign and malignant tumors, especially
gastric GISTs. Tumors of 2 cm in diameter are generally expected to behave in a benign
fashion. Tumors of &lt;5 cm in diameter are associated with a better survival rate than
those of 5-10 cm in diameter, which in turn have a better prognosis than those of &gt;10
cm in diameter. Degrees of cellularity and atypia have also been suggested as useful
criteria, but their reproducibility is more problematic. Based on all these information,
was considered the present case as a low-risk GIST, since the tumor specimen measured
less than 5 cm in diameter and showed no mitotic activity (zero mitoses in 50 HPF). For
those reasons was decided not to give adjuvant imatinib.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial source: none</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arezzo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Verra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Morino</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Transanal endoscopic microsurgery after neoadjuvant therapy for rectal
GIST</article-title>
          <source>Digestive and Liver Disease</source>
          <volume>43</volume>
          <year>2011</year>
          <fpage>921</fpage>
          <lpage> 924</lpage>
          <pub-id pub-id-type="pmid">21752740</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blay</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Bonvalot</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Casali</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>GIST consensus meeting panellists: Consensus meeting for the
management of gastrointestinal stromal tumours. Report of the GIST Consensus
Conference of 20-21 March 2004, under the auspices of ESMO</article-title>
          <source>Ann Oncol</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>566</fpage>
          <lpage>578</lpage>
          <pub-id pub-id-type="pmid">15781488</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiore</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Palassini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fumagalli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pilotti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tamborini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Stacchiotti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pennacchioli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Casali</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Gronchi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Preoperative imatinib mesylate for unresectable or locally advanced
primary gastrointestinal stromal tumors (GIST)</article-title>
          <source>Eur J Surg Oncol</source>
          <year>2009</year>
          <month>6</month>
          <volume>35</volume>
          <issue>7</issue>
          <fpage>739</fpage>
          <lpage>745</lpage>
          <pub-id pub-id-type="pmid">19110398</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ozaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Horimi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsuji</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nasu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Iwata</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Recurrent rectal GIST resected successfully after preoperative
chemotherapy with imatinib mesylate</article-title>
          <source>Int J Clin Oncol</source>
          <year>2008</year>
          <volume>13</volume>
          <fpage>355</fpage>
          <lpage>360</lpage>
          <pub-id pub-id-type="pmid">18704638</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lo</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Papachristou</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Finkelstein</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Conroy</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Schraut</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Ramanathan</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum:
report of a case</article-title>
          <source>Dis Colon Rectum</source>
          <year>2005</year>
          <volume>48</volume>
          <fpage>1316</fpage>
          <lpage>1319</lpage>
          <pub-id pub-id-type="pmid">15793646</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Machlenkin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pinsk</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tulchinsky</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>(2011) The effective of neoadjuvant imatinib therapy on outcome and
survival after rectal gastrointestinal stromal tumour</article-title>
          <source>Colon Dis</source>
          <volume>13</volume>
          <fpage>1110</fpage>
          <lpage>1115</lpage>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandal&#xE0;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pezzica</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tamborini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Guerra</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Lagonigro</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Forloni</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Barni</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Neoadjuvant imatinib in a locally advanced gastrointestinal stromal
tumour (GIST) of the rectum: a rare case of two GISTs within a family without a
familial GIST syndrome</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>2007</year>
          <month>8</month>
          <volume>19</volume>
          <issue>8</issue>
          <fpage>711</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="pmid">17625442</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nahas</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Nahas</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Marques</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Dias</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Pollara</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Cecconello</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Transanal endoscopic microsurgery (TEM): a minimally invasive
procedure for treatment of selected rectal neoplasms</article-title>
          <source>ABCD, arq. bras. cir. dig.</source>
          <year>2010</year>
          <volume>23</volume>
          <issue>1</issue>
          <fpage>35</fpage>
          <lpage>39</lpage>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salazar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Barata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Andr&#xE9;</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ven&#xE2;ncio</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Francisco</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Cravo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nobre-Leit&#xE3;o</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>First report of a complete pathological response of a pelvic GIST
treated with imatinib as neoadjuvant therapy</article-title>
          <source>Gut</source>
          <year>2006</year>
          <month>4</month>
          <volume>55</volume>
          <issue>4</issue>
          <fpage>585</fpage>
          <lpage>586</lpage>
          <pub-id pub-id-type="pmid">16531543</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>XJ</given-names>
            </name>
          </person-group>
          <article-title>The role of neoadjuvant imatinib mesylate therapy in
sphincter-preserving procedures for anorectal gastrointestinal stromal
tumor</article-title>
          <source>Am J Clin Oncol</source>
          <year>2011</year>
          <month>6</month>
          <volume>34</volume>
          <issue>3</issue>
          <fpage>314</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="pmid">20622646</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
